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doi:10.1016/j.jtcvs.2006.09.104bjective: The impact of lymph node involvement in lung metastasectomy from
xtrapulmonary malignancies is uncertain. We assessed the prognostic value of
ymph node status in lung metastasectomy and the prevalence of unexpected
ediastinal lymph node involvement after lymph node sampling or dissection.
ethods: From May 1998 to October 2005, 388 patients underwent 430 pulmonary
etastasectomies with curative intent. The clinical records of all patients who
nderwent radical lymph node dissection or sampling were reviewed retrospec-
ively. Survival was evaluated using the Kaplan–Meier method and comparison of
urvival curves by log–rank test.
esults: A total of 124 patients (61 men, mean age 59 years) underwent 139
ulmonary metastasectomies (56 wedge resections, 30 segmentectomies, 49 lobec-
omies, and 4 pneumonectomies with radical lymph node dissection [88] or sam-
ling [51]). Means of 9.4 lymph nodes and 2 lung metastases per intervention were
emoved. The median disease-free interval from primary treatment to lung metas-
asectomy was 49 months. Lymph node involvement was present in 25 patients
20%), in 10 (8%) at N1 stations (hilar or peribronchial) and in 15 (12%) at N2
tations (mediastinal), and in 7 (12.5%) after atypical resection and in 19 (23%) after
ypical resection. In 15 patients (12%) (60% of N patients), lymph node involve-
ent was unexpected. Estimated overall 5-year survival was 46%: It was 60% for
ubjects with no lymph node metastasis and 17% and 0% for those with N1 and N2
isease, respectively (P  .01).
onclusions: Lymph node involvement heavily affects prognosis after pulmonary
etastasectomies. In most patients, lymph node involvement was not revealed by
reoperative workup.
lthough the efficacy of surgical removal of lung metastases has been
demonstrated, fewer than 40% of patients benefit.1-5 For this reason there is
great interest to identify criteria and prognostic factors to improve selection
f surgical candidates and plan further therapeutic approaches. The main factor
redicting survival is complete surgical removal of all metastases2; others are the
isease-free interval, number of metastases, primary tumor type, presence of
xtrathoracic metastases, and levels of biological markers, such as carcinoem-
ryonic antigen for gastrointestinal cancers and alpha-fetoprotein for germ cell-
ancers.1-8
Lymph node staging was recently introduced as a prognostic factor for patients
ith resectable lung metastases.9-11 However, few data are available in the literature
n the prevalence of nodal involvement in these patients and its prognostic signif-
cance, so there is no agreement whether lymph node dissection should be routinely
erformed as part of metastasectomy.6-10,12
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TSThe aim of the present study was to determine the
revalence of occult regional lymph node metastasis and the
rognostic value in a retrospective series of patients who
nderwent radical lymph node dissection or sampling dur-
ng lung metastasectomy.
aterials and Methods
rom May 1998 to October 2005, 388 patients underwent 430 lung
etastasectomies with curative intent at the European Institute of
ncology. The records of all patients who received radical lymph
ode dissection or lymph node sampling were reviewed. Age, sex,
isease-free interval, primary tumor type, type of resection, num-
er and size of lung metastases, number of lymph nodes resected,
resence of hilar and mediastinal node metastases, and length of
ollow-up were abstracted and analyzed.
Indications for lung metastasectomy were controlled: primary
umor, absence of extrapulmonary metastasis or local recurrence at
he preoperative staging, and complete lung resection considered
ossible from chest computed tomography.
Positron emission tomography (PET) scan was not available
uring the entire time frame of the study period. All lesions that
ere suitable for nonanatomic resection on the basis of their size
nd position were removed by a wedge resection or tumorectomy;
n all other cases (large or centrally located metastases), an anatomic
esection was performed (segmentectomy, lobectomy, or pneumonec-
omy). Videothoracoscopy was not used because a manual palpation
f all lungs was routinely performed. The standard approach was
ateral muscle-sparing thoracotomy. Only in case of apical chest
umors with suspicious invasion of cervicothoracic junction structures
as a transmanubrial approach or hemiclamshell performed.
Although our previous experience indicated that 14% of patients
ndergoing lung metastasectomy had lymph node involvement,13
egional lymph node dissection in clinically negative cases was not
erformed routinely but according to the preference of each surgeon.
We considered a lymph node sampling to be the exploration of all
psilateral mediastinal stations with lymph node biopsy at the level of
t least 2 of them. We considered a radical lymph node dissection to
e performed at the following stations: R2, R4, 7, and R9 for right
ung metastasis and 5, 6, 7, and L9 for left lung metastasis.
The institutional review board was notified of our study, and
nformed consent to treat clinical data for research was obtained
rom the patients at the time of surgical resection.
tatistical Analysis
ime to death was defined as the time from surgery until death
rom any cause. All patients alive at last follow-up were right
ensored. Survival curves were estimated by the Kaplan–Meier
ethod, and the log–rank test was used to compare survival
etween groups. The chi-square or Fisher exact test was used to
Abbreviations and Acronyms
CI  confidence interval
HR  hazard ratio
PET positron emission tomographynalyze associations between categoric variables. A Cox pro- c
68 The Journal of Thoracic and Cardiovascular Surgery ● Apriortional hazards model was used to identify independent pre-
ictors of survival, with adjustment for relevant clinical covari-
tes. All statistical tests were 2-sided. The analyses were
erformed with the SAS statistical package version 8.2 (SAS
nstitute, Cary, NC).
esults
ediastinal lymph node dissection or sampling was per-
ormed in 124 patients. The mean age was 59 years (range
4-82 years); 61 were men and 63 were women. The median
isease-free time from primary tumor resection to first pul-
onary metastasectomy was 49 months (range 2-371
onths). A total of 139 pulmonary metastasectomies were
erformed in these patients: 56 wedge resections, 30 seg-
entectomies, 49 lobectomies, and 4 pneumonectomies.
adical lymph node dissection was performed in 88 proce-
ures, and sampling was performed in 51 procedures. A
ean of 9.4 (1308/139) lymph nodes were removed per
peration (4.6 lymph nodes for sampling and 12.1 lymph
odes for radical dissection). A mean of 2 lung metastases
ere resected per operation. Table 1 shows the frequency of
ymph node metastases and other characteristics. Lymph
ode involvement was found in 25 patients (20%); 10
atients (8%) had hilar station and 15 patients (12%) had
ediastinal station involvement (among these, 7 patients
ad both hilar and mediastinal metastases). In 10 of these
ases, involvement (hilar 6, mediastinal 4) was suspected
rom the presurgical workup, and in 15 of these cases
12%), lymph node metastasis was not revealed by staging
rocedures and was totally unexpected. Another 5 patients
ad clinically positive lymph nodes (among the group with
athologic negative lymph nodes). Overall, there were 109
atients with clinically negative lymph nodes, and the true
ate of occult nodal involvement was 13.7% (15/109). Even
f a small number of patients were available for each tumor
ype, we could observe that the frequency of nodal involve-
ent varied significantly according to primary site (Table 1).
atients with lung metastases from breast cancer, germ cell
ancers, and epithelial gynecologic cancers had signifi-
antly higher frequencies of nodal involvement than those
ith metastases from colon cancer. Nodal metastases were
ound in 7 of 56 (12.5%) atypical lung resections and in 19
f 83 (22.9%) typical resections (per procedure analysis;
 .18). Peribronchial or hilar node (N1) metastases oc-
urred in 3.5% and 9% of atypical and typical resections,
espectively, whereas mediastinal node metastases occurred
n 9% and 12% of atypical and typical resections, respec-
ively. Fifteen (4.9%) of the 303 lymph nodes removed
uring atypical resection were metastatic, compared with 71
6.7%) of the 998 lymph nodes removed by typical resection
P  .29).
The prevalence of nodal metastasis was not significantly
orrelated with the size of resected metastasis (P  .17).
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G
TSurvival
he mean postoperative follow-up was 31 months (range
-82 months). Estimated 5-year survival was 46% overall,
0% in N0, 17% in N1, and 0% in N2 (or N1  N2) cases
igure 1. Survival according to lymph node status after lung
ABLE 1. Prevalence of nodal involvement in lung metasta
umber of lymph nodes removed, number of lung metastas
No. of procedures
(patients)
No. with involved
nodes (%)*
otal 139 (124) 26 (18.7%)
typical resections (%)* 56 (47) 7 (12.5%)
ypical resections 83 (77) 19 (22.9%)
o. of metastases removed
1 80 (73) 14 (17.5%)
2 59 (51) 12 (20.3%)
ize of lung metastasis†
0-1 cm 7 (7) 1 (14.3%)
1-2 cm 42 (34) 7 (16.7%)
2-3 cm 38 (33) 5 (13.2%)
3-4 cm 22 (21) 5 (22.7%)
4 cm 29 (28) 8 (27.6%)
rimary tumor site
Colon 61 (54) 6 (9.8%)
Sarcoma 17 (15) 1 (5.9%)
Head/neck 10 (8) 1 (10.0%)
Urinary tract 17 (16) 3 (17.6%)
Breast 12 (11) 6 (50.0%)
Gynecologic 9 (8) 3 (33.3%)
Melanoma 6 (6) 2 (33.3%)
Germ cell 3 (3) 3 (100%)
Other/unknown 4 (3) 1 (25.0%)
Percentages calculated on the number of procedures. †Largest diameteetastasectomy. r
The Journal of ThoracicP  .01; Figure 1). Estimated 5-year survival was 47% in
hose with 1 lung metastasis, 57% in those 2 lung metasta-
es, and 31% in those with 3 or more metastases (P  .024;
igure 2).
omies in relation to primary cancer site, type of resection,
and maximum diameter of lung metastasis
P value
Extent of involvement
Hilum only (N1) (%)* Mediastinum (N1  N2 or N2) (%)*
11 (7.9%) 15 (10.8%)
2 (3.6%) 5 (8.9%)
.18 9 (10.8%) 10 (12.0%)
4 (5.0%) 10 (12.5%)
.67 7 (11.9%) 5 (8.5%)
1 (14.3%) 0 (0.0%)
5 (11.9%) 2 (4.8%)
1 (2.6%) 4 (10.5%)
1 (4.6%) 4 (18.2%)
.18 3 (10.3%) 5 (17.2%)
ference 2 (3.3%) 4 (6.6%)
1.00 1 (5.9%) 0 (0.0%)
.51 0 (0.0%) 1 (10.0%)
.34 2 (11.8%) 1 (5.9%)
.001 2 (16.7%) 4 (33.3%)
.04 1 (11.1%) 2 (22.2%)
.11 1 (16.7%) 1 (16.7%)
.001 1 (33.3%) 2 (66.7%)
.24 1 (25.0%) 0 (0.0%)
ng metastasis determined by pathologic exam.
igure 2. Survival according to number of lung metastasessect
es,
Reemoved.
and Cardiovascular Surgery ● Volume 133, Number 4 969
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G
TSBy univariate analyses, age, sex, primary tumor site,
isease-free interval, type of resection, type of lymph node
issection, and size of the largest metastasis had no impact
n survival (Table 2).
Among patients with positive nodes, no significant dif-
erence in overall survival was observed in cases of radical
ABLE 2. Univariate and multivariate analysis of 124 pa-
ients undergoing 139 lung metastasectomies with lymph
ode sampling
No. of
patients Dead
HR of death
(95% CI)
univariate
HR of death
(95% CI)
multivariate
ge (y)
50 28 15 1.00 1.00
50-59 31 9 0.47 (0.21-1.08) 0.71 (0.27-1.90)
60-69 33 17 0.84 (0.42-1.69) 1.22 (0.52-2.85)
70 32 11 0.56 (0.26-1.23) 1.27 (0.46-3.50)
ex
Men 61 28 1.00 1.00
Women 63 24 0.88 (0.51-1.51) 1.16 (0.53-2.51)
ize of mets (cm)
2.2 59 20 1.00 1.00
2.2 64 31 1.43 (0.81-2.51) 1.32 (0.65-2.69)
N status
pN0 100 36 1.00 1.00
pN 24 10 2.18 (1.20-3.97) 2.62 (1.14-6.01)
o. of mets
1 73 29 1.00 1.00
2 26 9 0.94 (0.44-1.99) 0.88 (0.35-2.22)
3 25 14 2.28 (1.19-4.37) 5.83 (2.35-14.5)
ype of resection
Atypical 47 14 1.00 1.00
Typical 77 38 1.52 (0.82-2.81) 1.93 (0.89-4.17)
ets  pN
pN0 with 1 or
2 mets
78 24 1.00 1.00
pN or
3 mets
46 28 3.11 (1.78-5.42) 5.19 (0.55-10.6)
isease-free
interval
24 mo 36 12 1.00 1.00
24-48 mo 43 23 1.75 (0.87-3.52) 1.82 (0.81-4.10)
48 mo 42 15 0.86 (0.40-1.83) 0.72 (0.29-1.79)
ite of primary
Colon 54 21 1.00 1.00
Breast 11 5 1.16 (0.44-3.07) 0.78 (0.21-2.86)
Melanoma 6 4 2.25 (0.77-6.59) 2.03 (0.57-7.24)
Head/neck 8 1 0.29 (0.04-2.18) 0.24 (0.03-2.01)
Urinary tract 16 8 1.31 (0.58-2.97) 1.52 (0.56-4.09)
Gynecologic 8 3 0.93 (0.28-3.13) 0.48 (0.09-5.28)
Germ cell 3 1 0.92 (0.12-6.86) 0.29 (0.02-3.57)
Other 3 2 2.28 (0.53-9.79) 2.19 (0.21-23.2)
Sarcoma 15 7 1.75 (0.74-4.12) 1.58 (0.60-4.21)
R, Hazard ratio; CI, confidence interval; mets, metastases. Largest diam-
ter of lung metastases determined pathologically.ymph node dissection or sampling (P  .36). d
70 The Journal of Thoracic and Cardiovascular Surgery ● ApriThe multivariate analysis showed that the nodal status
nd number of lung metastases were independent prognostic
actors for overall survival. For involved nodes, the hazard
atio (HR) for death was 2.62 (95% confidence interval [CI]
.14-6.01) for 3 or more lung metastases, and the HR of
eath was 5.83 (95% CI 2.35-14.5) (Table 2). The combi-
ation of nodal status and number of lung metastases pro-
uced 2 groups of patients with markedly differing prog-
oses: Those with pN0 and 1 or 2 metastases had a 5-year
urvival of 55%; those with pN and 3 or more metastases
most with 1 had the other) had a 5-year survival of 12%
P  .0001, log rank; HR of death 3.1, 95% CI 1.78-5.4,
igure 3).
iscussion
he role of lymph node dissection in lung metastasectomy and
he prognostic role of nodal involvement are still controversial
Table 3). In a series of 100 patients with colon cancer who
nderwent routine lymph node dissection during lung metas-
asectomy, involved lymph nodes were associated with poorer
rognosis (5-year survival 7% vs 50% in those with no positive
odes).6 Similarly, in a series of 70 lung metastasectomies with
omplete lymph node dissection,9 the 3-year survival of pa-
ients with negative nodes was 69%, but only 38% in those
ith positive nodes (P  .001); nodal status was the only
rognostic factor for survival in this series. Lymph node me-
astasis was also an independent predictor of survival in the
tudies of Pfannschmidt and colleagues.12,14 In contrast, the
ecent study of Loehe and colleagues10 found that lymph node
tatus had no effect on survival in a series of 71 lung metas-
asectomies from various primaries, 14.5% of which had me-
igure 3. Survival according to combination of the 2 independent
rognostic variables (pN status and number of metastases).iastinal metastasis. Kamiyoshihara and associates15 found no
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G
TSurvival difference between patients with and without lymph
ode involvement in a retrospective review of 28 patients
ndergoing lung metastasectomy and nodal dissection.
The main finding of our study is that involved lymph
odes identified during radical lymphadenectomy or sam-
ling as part of lung metastasectomy for extrapulmonary
rimaries had a major impact on survival: The nodal status
nd number of lung metastases were independent prognostic
actors. The combination of these 2 factors defined 2 groups
ith different prognoses: those with 1 or 2 metastases and
o nodal involvement (5-year survival, 60%) and those with
or more lung metastases and nodal involvement (5-year
urvival, 12%). An important issue in patients proposed for
ung metastasectomy is the frequency of nodal involvement,
articularly in view of the finding by most studies that nodal
nvolvement has a strong negative impact on survival. The
requency was 5% in the International Registry Report3 and
pproximately 15% in most reports,6,10,11 but sometimes
igher (28.6% and 37%).9,12 Twenty percent of our patients
18% of procedures) had lymph node involvement. More
evealing, however, is the frequency of unexpected (not
dentified in preoperative workup) lymph node involve-
ent, which was 13.5% in our study.
The incidence of lymph node metastasis was signifi-
antly influenced by primary tumor site, being low for
olorectal cancer and sarcoma (9% and 6.6%, respectively),
oderate for head and neck and urinary tract tumors (12%
nd 18%, respectively), and high for melanoma, gyneco-
ogic tract cancers, breast cancers, and germ cell cancers
33%, 38%, 54% and 100%, respectively). Even if a small
umber of cases are reported for each tumor type, these
ndings are in line with previous experience of high rates
f lymph node involvement in lung metastases from
elanoma16,17 and gynecologic tract tumors10 and a low
ABLE 3. Lymph node involvement in patients with lung
etastases and impact on survival in published series
irst author Year
Primary
site
5-y survival Percentage
positive LNN N
ebb 1979 Melanoma 50%
kumura 1996 Colon 15%
nternational
Registry
1997 Mix 14% 45% 5%
noue 2000 Colon 14% 49%
oehe 2001 Mix *22 mo 32 mo 14%
aito 2002 Colon 6.2% 53.6% 15%
rcan 2004 Mix no
sarcoma
20% 60% 29%
fannschmidt 2006 Mix 20 mo 64 mo 37%
eronesi 2006 Mix 9% 57% 20%
N, Lymph node. *Median survival.ate for sarcoma.9,18
The Journal of ThoracicWe found that the frequency of nodal involvement did
ot correlate with the number of resected lung metastases as
eported by others9,10 or the maximum diameter of the lung
esions. In contrast, the frequency of nodal involvement
ended to be higher for typical resections (23%) than for
typical resections (12%) (P  .18). In particular, patients
ndergoing typical resections had a higher frequency of N1
etastases than those who received atypical resection (11%
s 3.5%, respectively), suggesting differences in the extent
f lymph node resection at hilar, lobar, or segmental stations
y the 2 procedures (no segmental and peribronchial lymph
ode can be removed in case of wedge resection). In fact,
hen the number of positive nodes is divided by the total
umber of resected lymph nodes in the 2 groups of patients
typical vs atypical resection), a similar proportion of in-
olved nodes was found at N1 and N2 stations.
onclusions
lthough our study is limited by its retrospective nature and
he absence of evaluation of preoperative PET results, it
rovides strong evidence that N2 and N1 node involvement
n patients undergoing lung metastasectomy has a signifi-
ant impact on survival. The implication is that preopera-
ively confirmed involvement is a relative contraindication
or lung metastasectomy. Our second major finding was that
t least 13% of patients undergoing metastasectomy had
ymph node metastases that were not suspected from pre-
perative workup and that the frequency of involvement
orrelated with the primary site.
More accurate and sensitive preoperative staging proce-
ures are required. There is evidence that PET or computed
omography/PET may partially fulfill this requirement,13
lthough this requires confirmation by prospective study
ith the aim to avoid useless surgery and to identify patients
ho are candidates for multimodality treatments that may
ffer longer survival. Mediastinoscopy can also be consid-
red in some histologic subtypes. Considering the standard
ethods of staging available today, we can affirm that the
athologic examination of regional lymph nodes offers pa-
ients with resectable lung metastasis a more accurate stag-
ng and better determination of prognosis with the possi-
ility to administrate potentially beneficial multimodality
reatment.
eferences
1. Rusch VW. Pulmonary metastasectomy: current indication. Chest.
1995;107:322S-31S.
2. Matthay RA, Arroliga AC. Resection of pulmonary metastases. Am
Rev Respir Dis. 1993;148:1691-6.
3. The International Registry of Lung Metastases. Long-term results of
lung metastasectomy: prognostic analyses based on 5206 cases. J Tho-
rac Cardiovasc Surg. 1997;113:37-49.
4. Girard P, Baldeyrou P, Le Chevalier T, et al. Surgery for pulmonary
metastases: who are the 10-year survivors? Cancer. 1994;74:2791-7.5. Monteiro A, Arce N, Bernardo J, et al. Surgical resection of lung
metastases from epithelial tumors. Ann Thorac Surg. 2004;77:431-7.
and Cardiovascular Surgery ● Volume 133, Number 4 971
11
1
1
1
1
1
1
1
D
D
r
w
o
o
t
g
d
p
Y
s
p
t
s
p
r
s
b
W
s
p
f
t
o
w
a
m
l
m
d
P
o
p
r
a
n
l
m
l
a
s
r
a
t
s
s
p
t
t
d
d
t
n
t
n
s
l
d
o
a
e
I
y
w
s
m
d
a
t
General Thoracic Surgery Veronesi et al
9
G
TS6. Okumura S, Kondo H, Tsuboi M, et al. Pulmonary resection for
metastatic colorectal cancer: experiences with 159 patients. J Thorac
Cardiovasc Surg. 1996;12:867-74.
7. Cerfolio RJ, Allen MS, Deschamps C, et al. Pulmonary resection of
metastatic renal cell carcinoma. Ann Thorac Surg. 1994;57:339-44.
8. Inoue M, Ohta M, Iuchi K, et al. Benefits of surgery for patients with
pulmonary metastases from colorectal carcinoma. Ann Thorac Surg.
2004;78:238-44.
9. Ercan S, Nichols FC 3rd, Trastek VF, et al. Prognostic significance of
lymph node metastasis found during pulmonary metastasectomy for
extrapulmonary carcinoma. Ann Thorac Surg. 2004;77:1786-91.
0. Loehe F, Kobinger S, Hatz RA, et al. Value of systematic mediastinal
lymph node dissection during pulmonary metastasectomy. Ann Thorac
Surg. 2001;72:225-9.
1. Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165
patients with colorectal carcinoma: a prognostic assessment. J Thorac
Cardiovasc Surg. 2002;124:1007-13.
2. Pfannschmidt J, Klode J, Muley T, et al. Nodal involvement at the time
of pulmonary metastasectomy: experience in 245 patients. Ann Thorac
Surg. 2006;81:448-54.
3. Pastorino U, Veronesi G, Landoni C, et al. Fluorodeoxyglucose positron
emission tomography improves preoperative staging of resectable lung
metastasis. J Thorac Cardiovasc Surg. 2003;126:1906-10.
4. Pfannschmidt J, Hoffmann H, Muley T, et al. Prognostic factors for
survival after pulmonary resection of metastatic renal cell carcinoma.
Ann Thorac Surg. 2002;74:1653-7.
5. Kamiyoshihara M, Hirai T, Kawashima O, et al. The surgical treatment
of metastatic tumors in the lung: is lobectomy with mediastinal lymph
node dissection suitable treatment? Oncol Rep. 1998;5:453-7.
6. Faries MB, Bleicher RJ, Ye X, Essner R, Morton DL. Lymphatic
mapping and sentinel lymphadenectomy for primary and metastatic
pulmonary malignant neoplasms. Arch Surg. 2004;139:870-6.
7. Webb WR. Hilar and mediastinal lymph node metastases in malignant
melanoma. Am J Roentgenol. 1979;133:805-10.
8. Putnam JB. Secondary tumors of the lung. In: Shields TW, LoCicero
J, Ponn RB, eds. General Thoracic Surgery, 5th ed. Philadelphia:
Lippincott Williams & Wilkins; 2000:1555-76.
iscussion
r Vallieres (Seattle, Wash). Dr Veronesi, thank you for this
eview and for sending me all the material way ahead of time. That
as appreciated.
In this retrospective review covering 124 patients over a period
f 7 years, I think you have convincingly shown that the presence
f nodal metastasis in patients undergoing pulmonary metastasec-
omy carries a dismal prognosis, as others have previously sug-
ested but generally with less numerous series. From your survival
ata, it appears that the role of pulmonary metastasectomy is
robably limited to nonexistent in the presence of N2 disease.
our article brings 2 issues to discuss relating the role of nodal
ampling or dissection: first, the staging issues, and second, the
otential of any therapeutic issue of removing lymph nodes at the
ime of pulmonary metastasectomy.
First I’d like you to address a few questions regarding the
taging issue. Considering your data and a 0% 5-year survival in
atients with N2 disease, what is your practice now? Do you
ecommend routine mediastinal staging with mediastinoscopy de-
pite normal imaging? Do you restrict that only for patients with
reast, gynecologic, melanoma, or germ cell tumor primaries?
hat do you do now in Milan for these patients?
Dr Veronesi. One limitation of the study was that the role of PET
can was not well indicated in this series, but in a previous work I
ersonally analyzed the role of PET scan in lung metastasectomy and
ound that most N-positive patients were identified at PET scan. In
hat series we excluded some patients with nodal involvement because q
72 The Journal of Thoracic and Cardiovascular Surgery ● Aprif the PET scan, but I think that, as was recently reported in patients
ith lung cancer, PET with its high negative predictive value will be
ble to limit the role of mediastinoscopy. So in case of a PET-negative
ediastinum with a computed tomography contrast negative at that
evel, we do not use mediastinoscopy. In the case of PET-positive
ediastinum, I think the mediastinoscopy is a good tool to exclude
isease at that level. The problem of N1 disease remains because both
ET and mediastinoscopy are not precise tools to evaluate this level
f disease, so in these cases I think that thoracotomy is the only
ossibility.
Dr Vallieres. You showed that there was no survival difference
elating to the size of the metastases. What about the presence or
bsence of nodal involvement correlating to the size of the metastases?
Dr Veronesi. We did not find a significant correlation between
odal involvement and size of metastasis. However, we found that the
esion larger than 4 mm had a prevalence rate of nodal involve-
ent of 30% more than smaller lesions, so it may suggest that in
arge lesions such as this, larger than 4, sampling should be made.
Dr Vallieres. Do you mean 4 mm or 4 cm?
Dr Veronesi. Centimeters.
Dr Vallieres. As you have stated in your discussion by doing
n atypical resection, either a wedge or a tumorectomy, we under-
tage many of the patients. Would you thus advocate that we now
outinely stage N1 and N2 nodes when we are doing a video-
ssisted thoracic surgery wedge or an open-wedge metastasec-
omy?
Dr Veronesi. I am not convinced that in all cases we have to do
ampling or dissection (radical lymph node dissection). Maybe in a
mall lesion, a peripheral PET-negative metastasis, maybe from a
atient with sarcoma, we can avoid lymph node sampling because
here are some other disadvantages to this procedure, such as difficult
o redo a thoracotomy, for example, for recurrent metastasis.
Dr Vallieres. I’d like to explore the therapeutic role of nodal
issection/resection. Your data suggest that nodal sampling or
issection in these patients definitely allows for better staging of
heir disease. Is there also a potential therapeutic effect, benefit, of
odal dissection versus sampling in this scenario of metastasec-
omy? Did you look at the survival difference in patients with
ode-positive disease, whether they’d had a nodal dissection ver-
us just sampling? I understand that the numbers are small.
Dr Veronesi. We performed a separate analysis in the popu-
ation evaluating the role of radical versus sampling lymph nodes
issection, and no difference was found. Even regarding . . . (end
f cassette).
Dr Vallieres. During the study period did you perform medi-
stinoscopies in patients who had clinical N disease and as such
liminate these patients from the cohort you have just presented?
f you did, did you look at the survival of the individuals in whom
ou had identified N2 disease and did not operate versus those who
ere found to have N2 disease at surgery? Did they behave the
ame, or did the metastasectomy have an impact?
Dr Veronesi. This is a good question. We certainly performed
ediastinoscopy and excluded patients from surgery, but I have no
ata about their survival outcome.
Dr Vallieres. I enjoyed your presentation. I certainly encour-
ge you and your colleagues in Milan in continuing to prospec-
ively accrue information on these patients so that some of these
uestions will be answered in the future.
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